Preeclampsia is a pregnancy-specific hypertensive syndrome that causes substantial maternal and fetal morbidity and mortality. Recent evidence indicates that maternal endothelial dysfunction in preeclampsia results from increased soluble Fms-like tyrosine kinase-1 (sFlt-1), a circulating antiangiogenic protein. Factors responsible for excessive production of sFlt-1 in preeclampsia have not been...

OBJECTIVES To examine the effect of diazoxide on hypoxia-induced soluble fms-like tyrosin kinase-1 (sFlt-1) release in JEG-3 choriocarcinoma cells. METHODS Cells were cultured under normoxia (20% O2) or hypoxia (1% O2), and expression of sFlt-1 mRNA and protein release was determined by quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) assays and enzyme-linked i...

PURPOSE Vascular endothelial growth factor (VEGF) is a potent angiogenic agent and plays a major role in tumor growth and metastases. We have previously reported the locoregional (i.p.) delivery of adenovirus-mediated antiangiogenic soluble FLT-1 (sFLT-1; a naturally encoded potent VEGF antagonist) gene therapy to inhibit VEGF action in a murine ovarian carcinoma model. This study was predicate...

Preeclampsia is a potentially life threatening disorder of pregnancy which presents with raised blood pressure and proteinuria after twentieth week of gestation. It is one of the leading and mystical causes of maternal and fetal mortality worldwide. Abnormal placentation is suggested to be possibly the key feature of this disorder. Preeclampsia has been attributed to the presence of a circulati...

OBJECTIVE To determine in vivo whether LH supplementation during the late follicular phase induces ovarian follicle angiogenesis in humans, as reflected by vascular endothelial growth factor (VEGF)-A, its soluble receptor sFlt-1, and placental growth factor (PlGF) expression. DESIGN Randomized, double-blind, placebo-controlled study. SETTING Academic tertiary care medical center. PATIENT(...

BACKGROUND Plasma concentrations of sFlt-1, the soluble form of the vascular endothelial growth factor receptor (VEGF), markedly increase during coronary artery bypass graft (CABG) surgery with extracorporeal circulation (ECC). We investigated if plasma sFlt-1 values might be related to the occurrence of surgical complications after CABG. METHODS Plasma samples were collected from the radial ...

To assess the diagnostic performance of angiogenic biomarkers in determining need for delivery seven days women with late preterm preeclampsia. In a prospective observational cohort study 36 maternity units across England and Wales, we studied accuracy placental growth factor (PlGF) sFlt-1 risk complications requiring (34+0 to 36+6 weeks' gestation) Angiogenic were measured using Quidel Roche (...

INTRODUCTION The discovery of new treatments that prevent or treat preeclampsia would be a major advance. Antiangiogenic factors soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG) are secreted in excess from the placenta, causing hypertension, endothelial dysfunction, and multiorgan injury. We recently identified metformin and esomeprazole as potential treatments for preecl...

Exogenous VEGF To the Editor: Results from the VEGF in Ischemia for Vascular Angiogenesis (VIVA) clinical trial, which demonstrated the therapeutic use of vascular endothelial growth factor (VEGF) in angina, were presented at the 48th Scientific Sessions of the American College of Cardiology.1 These results indicated that no significant difference existed in the symptoms or clinical events of p...

BACKGROUND Our primary objective was to establish a cutoff value for the soluble fms-like tyrosine kinase 1(sFlt-1)/placental growth factor (PlGF) ratio measured using the Elecsys assay to predict late-onset preeclampsia in low-risk pregnancies. Our secondary objective was to evaluate the ability of combination models using Elecsys data, second trimester uterine artery (UtA) Doppler ultrasonogr...